Among cancers, scientists have spent their entire research careers looking for cellular similarities that may lead to a single cure for many cancers –– the rare chance to have a single answer to a multifaceted problem. In 1997, scientists discovered a gene that they believed was the key to cellular immortality. Telomerase Reverse Transcriptase, or TERT, is a catalytic piece of telomerase, and while cellular immortality sounds like a good idea, it is actually how cancerous tumors grow and proliferate in cancer patients.
In the late nineties, the unanswered question was whether or not TERT was a cancer-causing gene. Scientists spent the next decade hunting for the mutations that activate it but no one was able to find mutations in TERT. Two years ago, two groups of researchers discovered that TERT didn't have any mutations at all. Instead, the mutations were occurring in the regulatory region that controls the expression of the gene. These mutations showed up in melanoma, and in many cancers found in the brain, liver and bladder.
"It was at that point that I realized we had all the tools and expertise in our lab to understand the mechanisms of these mutations. What my lab did with our collaborators at CU's Anschutz Medical Campus was to trace the effect of the mutation from the DNA to the increased RNA levels, to the increased protein levels, to the increased telomerase levels," says BioFrontiers Director Tom Cech, who recently published his team's findings in the journal Science. "We were able to show this effect in 23 bladder cancer cell lines by comparing those with mutations to those without mutations."
Bladder cancer cell lines were available at Anschutz and Cech's research team worked with colleagues there, including Dan Theodorescu, Director of the CU Cancer Center, to use those lines because their cellular workings could be applied to a variety of different cancers. Bladder cancer itself is no small threat. The National Institutes of Health report that this cancer caused more than 15,000 deaths in 2014 alone, and nearly 75,000 new cases were diagnosed in the same year. Treatment for this type of cancer is not easy either, involving some combination of chemotherapy, biological therapy with bacteria or completely removing the bladder.
One of the most valuable parts of the study was the team of collaborators doing the research including: Staff Scientist, Art Zaug; Postdoctoral Researcher, Sumit Borah; Graduate Student Linghe Xi, and an undergraduate with a triple major in biology, biochemistry and neuroscience, Natasha Powell. This team worked across the two CU campuses to gain access to unique bladder cancer cell lines available at the Anschutz Medical Campus. The team in the Cech lab also had a process for measuring the number of TERT protein molecules and the very small changes in enzyme activity within cells.
Using these tools the research team pushed beyond the current limitations of technology in measuring molecular changes within cells. Computer analysis of the data further confirmed that a finding of high telomerase levels could predict whether a patient's bladder cancer was fatal or survivable. At some point in the future, doctors may be able to measure telomerase activity in cancer patients and prescribe a treatment schedule according to the severity of the cancer. Using this technique, telomerase could be a biomarker for certain cancers and Cech hopes his research will give medical diagnostic companies the knowledge they need to develop a test that could be used easily in a doctor's office.
"We hope that this research will stimulate drug companies to find telomerase inhibitors to slow and change cancer to a more treatable version. We're also interested in seeing if this research applies to other types of cancers, which would create an opportunity where a single drug could impact many different kinds of cancers," says Cech.
Explore further: Chromosome 'bumper repair' gene predicts cancer patient outcomes
More information: TERT promoter mutations and telomerase reactivation in urothelial cancer, Published Online February 5 2015 Science 27 February 2015: Vol. 347 no. 6225 pp. 1006-1010 . DOI: 10.1126/science.1260200
Medical Xpress on facebook
Related Stories
Chromosome 'bumper repair' gene predicts cancer patient outcomes
Like a car's front and back bumpers, your cell's chromosomes are capped by "telomeres" that protect this genetic material against deterioration. Still, after enough replications, a chromosome's telomeres ...
Three out of every four cases of bladder cancer display mutations in the same gene
Researchers from the Spanish National Cancer Research Centre (CNIO) have discovered that more than 70% of bladder tumours display somatic mutations in the TERT gene (telomerase reverse transcriptase). The TERT gene is involved ...
Mutations linked to repair of chromosome ends may make emphysema more likely in smokers
Mutations in a gene that helps repair damaged chromosome ends may make smokers—especially female smokers—more susceptible to emphysema, according to results of a new study led by Johns Hopkins Kimmel Cancer ...
Study discovers mutation role involved in 75 percent of glioblastomas, melanomas
Researchers at the University of Louisville's James Graham Brown Cancer Center have identified for the first time mutations that destabilize a DNA structure that turns a gene off. These mutations occur at four specific sites ...
New mutations driving malignant melanoma discovered
Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't ...
Recommended for you
Smokers at twice risk of prostate cancer recurring after surgery
Current smokers, and those who have quit smoking less than 10 years previously, have twice the risk of a recurrence of prostate cancer after surgery, according to new research presented at the European Association ...
The challenges of diagnosing cancers earlier: a GP's perspective
As GPs, we know that too many of our patients worry about wasting our time – a point underlined by a recent Cancer Research UK-funded study. ...
Popular artificial sweetener could lead to new treatments for aggressive cancers
Saccharin, the artificial sweetener that is the main ingredient in Sweet 'N Low, Sweet Twin and Necta, could do far more than just keep our waistlines trim. According to new research, this popular sugar substitute ...
Stress management techniques improve long-term mood and quality of life
A new study shows that providing women with skills to manage stress early in their breast cancer treatment can improve their mood and quality of life many years later. Published early online in Cancer, a peer-reviewed journa ...
New potential for personalized treatments in bowel cancer
Scientists have found that genetic changes in bowel tumours are linked to the way the body's immune system responds to the cancer, according to research published today in the journal Oncoimmunology.
Vitamin D may keep low-grade prostate cancer from becoming aggressive
Taking vitamin D supplements could slow or even reverse the progression of less aggressive, or low-grade, prostate tumors without the need for surgery or radiation, a scientist will report today.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
Among cancers, scientists have spent their entire research careers looking for cellular similarities that may lead to a single cure for many cancers –– the rare chance to have a single answer to a multifaceted problem. In 1997, scientists discovered a gene that they believed was the key to cellular immortality. Telomerase Reverse Transcriptase, or TERT, is a catalytic piece of telomerase, and while cellular immortality sounds like a good idea, it is actually how cancerous tumors grow and proliferate in cancer patients.
In the late nineties, the unanswered question was whether or not TERT was a cancer-causing gene. Scientists spent the next decade hunting for the mutations that activate it but no one was able to find mutations in TERT. Two years ago, two groups of researchers discovered that TERT didn't have any mutations at all. Instead, the mutations were occurring in the regulatory region that controls the expression of the gene. These mutations showed up in melanoma, and in many cancers found in the brain, liver and bladder.
"It was at that point that I realized we had all the tools and expertise in our lab to understand the mechanisms of these mutations. What my lab did with our collaborators at CU's Anschutz Medical Campus was to trace the effect of the mutation from the DNA to the increased RNA levels, to the increased protein levels, to the increased telomerase levels," says BioFrontiers Director Tom Cech, who recently published his team's findings in the journal Science. "We were able to show this effect in 23 bladder cancer cell lines by comparing those with mutations to those without mutations."
Bladder cancer cell lines were available at Anschutz and Cech's research team worked with colleagues there, including Dan Theodorescu, Director of the CU Cancer Center, to use those lines because their cellular workings could be applied to a variety of different cancers. Bladder cancer itself is no small threat. The National Institutes of Health report that this cancer caused more than 15,000 deaths in 2014 alone, and nearly 75,000 new cases were diagnosed in the same year. Treatment for this type of cancer is not easy either, involving some combination of chemotherapy, biological therapy with bacteria or completely removing the bladder.
One of the most valuable parts of the study was the team of collaborators doing the research including: Staff Scientist, Art Zaug; Postdoctoral Researcher, Sumit Borah; Graduate Student Linghe Xi, and an undergraduate with a triple major in biology, biochemistry and neuroscience, Natasha Powell. This team worked across the two CU campuses to gain access to unique bladder cancer cell lines available at the Anschutz Medical Campus. The team in the Cech lab also had a process for measuring the number of TERT protein molecules and the very small changes in enzyme activity within cells.
Using these tools the research team pushed beyond the current limitations of technology in measuring molecular changes within cells. Computer analysis of the data further confirmed that a finding of high telomerase levels could predict whether a patient's bladder cancer was fatal or survivable. At some point in the future, doctors may be able to measure telomerase activity in cancer patients and prescribe a treatment schedule according to the severity of the cancer. Using this technique, telomerase could be a biomarker for certain cancers and Cech hopes his research will give medical diagnostic companies the knowledge they need to develop a test that could be used easily in a doctor's office.
"We hope that this research will stimulate drug companies to find telomerase inhibitors to slow and change cancer to a more treatable version. We're also interested in seeing if this research applies to other types of cancers, which would create an opportunity where a single drug could impact many different kinds of cancers," says Cech.
Explore further: Chromosome 'bumper repair' gene predicts cancer patient outcomes
More information: TERT promoter mutations and telomerase reactivation in urothelial cancer, Published Online February 5 2015 Science 27 February 2015: Vol. 347 no. 6225 pp. 1006-1010 . DOI: 10.1126/science.1260200
Medical Xpress on facebook
Related Stories
Chromosome 'bumper repair' gene predicts cancer patient outcomes
Like a car's front and back bumpers, your cell's chromosomes are capped by "telomeres" that protect this genetic material against deterioration. Still, after enough replications, a chromosome's telomeres ...
Three out of every four cases of bladder cancer display mutations in the same gene
Researchers from the Spanish National Cancer Research Centre (CNIO) have discovered that more than 70% of bladder tumours display somatic mutations in the TERT gene (telomerase reverse transcriptase). The TERT gene is involved ...
Mutations linked to repair of chromosome ends may make emphysema more likely in smokers
Mutations in a gene that helps repair damaged chromosome ends may make smokers—especially female smokers—more susceptible to emphysema, according to results of a new study led by Johns Hopkins Kimmel Cancer ...
Study discovers mutation role involved in 75 percent of glioblastomas, melanomas
Researchers at the University of Louisville's James Graham Brown Cancer Center have identified for the first time mutations that destabilize a DNA structure that turns a gene off. These mutations occur at four specific sites ...
New mutations driving malignant melanoma discovered
Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't ...
Recommended for you
Smokers at twice risk of prostate cancer recurring after surgery
Current smokers, and those who have quit smoking less than 10 years previously, have twice the risk of a recurrence of prostate cancer after surgery, according to new research presented at the European Association ...
The challenges of diagnosing cancers earlier: a GP's perspective
As GPs, we know that too many of our patients worry about wasting our time – a point underlined by a recent Cancer Research UK-funded study. ...
Popular artificial sweetener could lead to new treatments for aggressive cancers
Saccharin, the artificial sweetener that is the main ingredient in Sweet 'N Low, Sweet Twin and Necta, could do far more than just keep our waistlines trim. According to new research, this popular sugar substitute ...
Stress management techniques improve long-term mood and quality of life
A new study shows that providing women with skills to manage stress early in their breast cancer treatment can improve their mood and quality of life many years later. Published early online in Cancer, a peer-reviewed journa ...
New potential for personalized treatments in bowel cancer
Scientists have found that genetic changes in bowel tumours are linked to the way the body's immune system responds to the cancer, according to research published today in the journal Oncoimmunology.
Vitamin D may keep low-grade prostate cancer from becoming aggressive
Taking vitamin D supplements could slow or even reverse the progression of less aggressive, or low-grade, prostate tumors without the need for surgery or radiation, a scientist will report today.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment